



## "Clicking" Gene Therapeutics: A Successful Union of Chemistry and Biomedicine for New Solutions

Astakhova, Kira; Ray, Roslyn; Taskova, Maria; Uhd, Jesper; Carstens, Annika; Morris, Kevin

*Published in:*  
Molecular Pharmaceutics

*Link to article, DOI:*  
[10.1021/acs.molpharmaceut.7b00765](https://doi.org/10.1021/acs.molpharmaceut.7b00765)

*Publication date:*  
2018

*Document Version*  
Peer reviewed version

[Link back to DTU Orbit](#)

*Citation (APA):*  
Astakhova, K., Ray, R., Taskova, M., Uhd, J., Carstens, A., & Morris, K. (2018). "Clicking" Gene Therapeutics: A Successful Union of Chemistry and Biomedicine for New Solutions. *Molecular Pharmaceutics*, 15(8), 2892-2899. <https://doi.org/10.1021/acs.molpharmaceut.7b00765>

---

### General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.



Published in final edited form as:

*Mol Pharm.* 2018 August 06; 15(8): 2892–2899. doi:10.1021/acs.molpharmaceut.7b00765.

## “Clicking” gene therapeutics: A successful union of chemistry and biomedicine for new solutions

Kira Astakhova<sup>1,\*</sup>, Roslyn Ray<sup>2</sup>, Maria Taskova<sup>1</sup>, Jesper Uhd<sup>1</sup>, Annika Carstens<sup>1</sup>, and Kevin Morris<sup>2,\*</sup>

<sup>1</sup>Department of Chemistry, Technical University of Denmark, 206 Kemitovet, 2800 Kgs Lyngby, Denmark

<sup>2</sup>Center for Gene Therapy, City of Hope – Beckman Research Institute and Hematological Malignancy and Stem Cell Transplantation Institute at the City of Hope. 1500 E. Duarte Rd., Duarte, CA, 91010, USA

### Abstract

The use of nucleic acid, DNA and RNA, based strategies to disrupt gene expression as a therapeutic is quickly emerging. Indeed, synthetic oligonucleotides represent a major component of emerging gene therapeutics. However, the efficiency and specificity of intracellular uptake for non-modified oligonucleotides is rather poor. Utilizing RNA based oligonucleotides as therapeutics is even more challenging to deliver, due to extremely fast enzymatic degradation of the RNAs. Like unmodified oligonucleotides, RNAs also get rapidly degraded *in vivo* and demonstrate large off-target binding events when they can reach and enter the desired target cells. One approach that holds much promise is the utilization of “click chemistry” to conjugate receptor or cell specific targeting molecules directly to the effector oligonucleotides. We discuss here the applications of the breakthrough technology of CuAAC “click-chemistry” and the immense potential in utilizing “click chemistry” in the development of new age targeted oligonucleotide therapeutics.

### Keywords

Click Chemistry; siRNA; non-coding RNA; Protein conjugates

## 1. Introduction

Gene therapy is an emerging approach that targets intracellular nucleic acids, those DNA and RNAs, associated with human diseases. Synthetic oligonucleotides represent a major type of currently used gene therapeutics. However, the efficiency and specificity of intracellular uptake for non-modified oligonucleotides is poor, with the vast majority trafficking directly to the liver<sup>1</sup>. Utilizing RNA therapeutics are even more challenging to deliver, due to extremely fast enzymatic degradation of the RNAs. Like unmodified

\*Corresponding author: kiraas@kemi.dtu.dk and kmorris@coh.org.

oligonucleotides, RNAs also get rapidly degraded *in vivo* and show large off-target binding even when they can reach and enter the desired target cells.

Clearly, creating a successful gene therapeutic is not limited to ensuring a successful base-pairing of a therapeutic to its target, but also ensuring stability and cell target specificity. Finding a suitable delivery carrier and enhancing the target specificity for gene therapeutics are both crucial key components required to advance oligonucleotide and RNA based therapeutics to a clinically relevant setting. Indeed, currently stability and receptor or cell targeting effectors can be added to both oligonucleotides and RNAs by conjugation with other biomolecules. Recent successful examples include oligonucleotide-lipid, oligonucleotide-carbohydrate and oligonucleotide-peptide conjugates (reviewed in<sup>2</sup>). An alternative to direct conjugations is the use of nanoparticles to shuttle therapeutic oligonucleotides with (in)organic polymers, small molecules and other biomolecules. The advantage of nanoassemblies is their relatively simple preparation compared to bioconjugation. However, nanoparticles formed by non-covalent interactions between molecules may inevitably prove to be unstable and require very fast delivery options, which are not available to date (reviewed in<sup>3</sup>).

Charged, chemically complex and sensitive biomolecules put limitations on the chemistry applied to link them. Click chemistry refers to a broad group of methods unified by the general concept of simple, biology-friendly and bioorthogonal procedures that conjugate molecules in a specific fashion. A breakthrough in click chemistry has been the development of copper-catalyzed click chemistry, CuAAC, by Sharpless, Finn et al. (2002). Rapidly after the discovery of CuAAC click-chemistry, the method was extended to the copper-free approach strain promoted click chemistry, or SPAAC, Diels-Alder, thiol-Michael click reactions. Today, several classical organic reactions have been modified to a “click” version. Each has its advantages and disadvantages and some can even be performed directly in live cells. With regards to gene therapy, CuAAC and SPAAC play a key role in creating decorated therapeutic DNA, RNA and their synthetic analogues, most of which have to date been evaluated *in vitro* (Figure 1). This is mainly due to the simplicity of the procedure, broad accessibility of the reagents and simple work up. However, new methods allow for the attachment of different modifications to one gene therapeutic, which potentially could be beneficial for *in vivo* applications. Indeed, a method to directly conjugate cell receptor targeted proteins, aptamers etc., to oligonucleotides or therapeutic RNAs could revolutionize oligonucleotide therapeutics.

Here in honor of one of the founders of “click chemistry”, Professor M.G. Finn’s 60<sup>th</sup> birthday, we review the current applications of click chemistry, CuAAC in particular the generation of new oligonucleotides and their nanoassemblies as therapeutic modalities.

## 2. Emerging targets in gene therapy and use of synthetic biomolecules

Therapeutic oligonucleotide strategies are promising owing to the fact they are designed *a priori* to be specific towards their target, with minimal off-target effects<sup>4</sup>. As such, targeting a single gene or RNA species with an oligonucleotide is thought to be a more effective approach in various diseases where drug approaches have shown reduced or limited efficacy.

However, limitations in delivering these molecules to the host, as well as identifying their distribution and target efficiency into target cells in a multicellular environment, have hampered the progression of these strategies into the clinic. Click chemistry provides a promising approach to generate oligonucleotides that can be delivered into target cells safely and with a high efficiency. Current strategies are in their infancy and have to date been mainly proof-of-concept. Most research to date focuses on different delivery strategies and visualization strategies of oligonucleotides being delivered into their cellular targets.

Recent studies have used click-chemistry to mediate the construction of nanoparticles that are loaded with their oligonucleotide cargo for efficient delivery into cells<sup>5-6</sup>. O'Brien et al., developed a new method called "SnapFect" using a nucleic acid complex with a bio-orthogonal group and a modified cell surface to recognize and deliver the oligonucleotide complex into the cell<sup>7</sup>. This strategy had minimal toxicity, few steps, was highly efficient and is compatible with siRNA, CRISPR and microfluidic technology. The authors also found that this method is amendable to work in stem and primary cells. Other authors have developed moieties that may help to control gene silencing *in vivo*. Harun et al., developed siRNA molecules conjugated to a poly(*N*-isopropylacrylamide) moiety that behaves as a coil-globule that changes its conformation with heat, with an optimal conformation at 35 °C<sup>8</sup>. The conformation results in accessibility of the siRNA to the RNA induced silencing complex. The authors tested the thermo-responsive siRNA conjugate and found that they were able to induce gene silencing at higher temperatures<sup>8</sup>.

Immunotherapy is a promising strategy in cancer therapy, and has shown recent success with the use of oncolytic viruses and CAR-T cell therapies. However, these strategies are expensive. As such, the use of other chemical adjuvants, such as cytokines, small oligonucleotides, or cancer antigens may be a more cost effective approach, despite their limited success to date.<sup>9</sup> One innovative approach recently developed cell lines to express chemically modified glycan carrying azide moieties, which subsequently allowed the cells to be clicked with different adjuvants, including ODNs. These cells were found to be able to stimulate macrophages *in vitro*, and when injected into mice, resulted in significantly smaller tumor sizes, than the control cells. Additionally, when mice were re-challenged with unmodified cells, no new tumors developed, suggesting broad protection from immune system targeting of the tumor<sup>9</sup>.

Click chemistry approaches have been developed and effectively used to conjugate fluorescent molecules, 5' caps, lipids, polysaccharides and peptides to RNA molecules<sup>10</sup>. Further, "click chemistry" has been developed as a strategy to circularize RNA<sup>10</sup>. Others have found using "click chemistry" that bio-conjugating mRNA with different polyamines at the 5' cap, increased formation of poly-ion complexes (PICs) and their binding to initiation factor 4E to increase translational efficiency of the mRNA target *in vitro*<sup>11</sup>. These technologies may help to better understand gene regulation and result in the development of smarter strategies that have discreet and specific effects on their intended targets, by visualizing where these siRNA conjugates are delivered to *in vivo* and by using the most relevant moieties to obtain the best siRNA conjugates to effectively deliver and target the appropriate cells for treatment. Other uses of click-chemistry have been to develop better labelling of RNA *in vitro* and *in vivo* to better profile RNA populations in distinct cellular

populations.<sup>12–13</sup> Furthermore, click chemistry has also been shown to be an effective tool to analyze the transport of stem cells to different locations<sup>14–15</sup> and has been used to understand the molecular dynamics and potential heterogeneity in drug activity *in vivo*<sup>16</sup>.

While progressive steps have been made in creating better deliverable molecules for gene therapy, few studies have been focused on a specific disease using an RNA-conjugate to mediate a positive medical outcome. The current strategies suggest that using the tool-box that click-chemistry affords, creating or redeveloping old strategies with new moieties for better delivery, enhanced uptake, and increased specificity into target cells, may result in new pathways for gene therapy. Indeed, research by our group(s) has focused largely on the use of peptide moieties that have shown to have great potential in overcoming the cell membrane to deliver its siRNA cargo to effect gene silencing for both HIV<sup>17</sup> and cholesterol regulation<sup>18</sup>.

### 3. Growing role of click chemistry in the development of gene therapeutics

Since the first reports on click chemistry for gene therapeutics,<sup>19–20</sup> the original CuAAC approach has been extended by alternative chemical strategies. Wiessler *et al.*, explored the Diels Alder click chemistry for therapeutic peptide nucleic acids (PNA; Figure 2)<sup>21</sup>. Several groups have demonstrated that PNA conjugates created by click chemistry have advantageous delivery properties compared to unconjugated precursors. In one body of work, Pipkort *et al.*, applied a similar approach to Diels Alder click, for cell-specific fluorescence imaging using PNA probes.<sup>22</sup> Using modular PNA probes allowed for the combination of the imaging and therapeutic activities in one PNA molecule. The mRNA product of the cysteine protease cathepsin B (CtsB) gene was imaged and simultaneously degraded using the peptide-PNA conjugate. The degradation was completed by adding a cleavage site to the CtsB complementary PNA probe. Further, Wojciechowska *et al.*, used click chemistry to make cell penetrating peptide (CPP) attached to PNA for atherosclerosis treatment, although the affinity to target hSTAT1 mRNA was demonstrated only *in vitro*<sup>23</sup>. The toxicity of PNA has been reported by several groups<sup>24–25</sup>, however it is not commented on in the aforementioned PNA click papers.

For therapeutic applications, there is a need for purification from any residual copper that can be left in the product of the CuAAC reaction. This is particularly important when cell penetrating and other peptides are clicked, due to the high affinity of amino acids to copper<sup>27–28</sup>. One approach is the use of Tangential flow filtration (TFF) purification that yields hundreds of grams of clicked biomolecules without any sign of toxicity in cells or *in vivo*<sup>29</sup>. Another strategy is using a copper-free click reaction. Wang *et al.*, used SPAAC to modify DNA with diverse functionalities<sup>30</sup>. SPAAC has advantages of high reaction rate at ultramild conditions when the two molecules to be reacted have no steric hindrance. However, the rate of SPAAC can be lower compared to CuAAC when clicking longer peptides (> 20 amino acids) to oligonucleotides<sup>31</sup>.

Phosphorodiamidite morpholino oligonucleotides (PMO) conjugated with cell-penetrating peptides exhibit a high potential for application as therapeutics for Duchenne muscular dystrophy<sup>32</sup>. Conjugates were initially screened using a selection of peptide conjugates

(SELPEPCON) procedure and then the best hits were tested in cells. The SELPEPCON procedure is beneficial for the selection of bioactive peptides that suggest the possibility of crossing the blood-brain barrier through the conjugates and simultaneously being time and cost effective for therapeutic screening<sup>32</sup>.

Since the late 2000s, most studies on click chemistry for gene therapy have used nanomaterials, being beneficial for the delivery and activity of gene therapeutics. Ghosh and Hamilton developed thermosensitive dendrimers based on G-quadruplex forming CG rich sequences<sup>33</sup>. They used different metal ion concentrations to drive the assembly which was confirmed by imaging. DNA-microcapsules prepared by Cavaleri et al. contained the hydrophobic core built from a poly N-isopropylacrylamide (PNIPAM) polymer and reactive “click” domains<sup>34</sup>. The products were decorated with DNA and poly ethylene glycol (PEG) and showed higher stability than the analogues that did not contain the PNIPAM hydrophobic core (Figure 3A).

Clicking cargos for gene therapeutics is another recent approach. Alshaer *et al.*, functionalized liposomes with an anti-CD44 aptamer via a thiol-maleimide click reaction, for selective targeting of cancer cells – Fig. 3 B)<sup>35</sup>. Uptake was proven in two CD44(+) human cancer cell lines, lung cancer A549 and breast cancer MDA-MB-231. A new cyclodextrin derivative CD-PLLD, consisting of a beta-cyclodextrin core and poly-L-lysine dendron, efficiently delivered siRNA encoding plasmid to cancer HNE-1 cells<sup>36</sup>. Simultaneously, a docetaxel was delivered. This star-shaped copolymer of cyclodextrin showed high activity, better blood compatibility and also lower cytotoxicity compared to the controls. It is exciting that clicked modified cyclodextrins have also been found to be capable of siRNA delivery to neurons<sup>37</sup>. Furthermore, low toxicity and high stability in serum has been confirmed for these vectors.

As to the specificity, additional modifications such as LNA are helpful to decrease off-target binding<sup>27</sup>. Decorating DNA with several peptide units resulted in improved stability and target recognition specificity of antisense oligonucleotides that target *BRAFV600E* oncogene. The CuAAC method gave good yields of double-labelled products as well. A “clickable” LNA variant has been suggested for miRNA targeting within LNA/DNA probes<sup>38</sup>. Besides often-applied sugar modification and terminal attachment by click chemistry, nucleobases can be modified by click chemistry as well. This is often applied when using clickable triphosphates (TPPs), due to better yields upon enzymatic incorporation than for sugar-modified TPPs. Also, the modification can be done post-synthetically with a broad range of azides. Xiong *et al.*, applied 8-aza-7-deazaguanine oligonucleotides to create branched Y-shaped DNA<sup>39</sup>. Annealing of branched DNA with complementary oligonucleotides yielded well defined nanostructures. Selective target recognition was also confirmed by *in vitro* assays.

In the last decade, focus has shifted from DNA to RNA therapeutics. As for DNA and its analogues, chemical modifications are compulsory for RNA therapeutics to increase stability *in vivo* and to ensure the specific delivery and intracellular uptake. Recent studies show that conjugation of therapeutic siRNA with fatty acids and carbohydrate residues benefit the therapeutic performance of RNA (RNA-galnac and RNA-fa papers<sup>40–42</sup>). For these

molecules, maleimide and *N*-Hydroxysuccinimide (NHS) chemistry is being used. Most methods are developed for DNA conjugation and do not meet the additional requirement of mild conditions needed for RNA modification. Growing applications in RNA therapy stimulate rapid development of bioconjugation methods that allow RNA labelling in high yields and purity<sup>43–44</sup>(Figure 5).

#### 4. Comparison of “clicked” gene therapeutics to alternatives

Although much progress has been made on the click chemistry of therapeutic oligonucleotides and their delivery vesicles, critical points that need to be addressed are their potential toxicity and possibility to scale-up production. TFF purification, which has been mentioned previously, is a good way to scale up the CuAAC reaction<sup>29</sup>. Moreover, as has been described by Jones *et al.*, click modification can affect the uptake pathway for therapeutics<sup>30</sup>. Trafficking determines the fate of a therapeutic inside the cell. Therefore, tracking studies are crucial to get structure-activity relationships for conjugates. Lastly, reducing the price of gene therapy is of crucial importance<sup>48</sup>.

The performance of available clicked therapeutics vs. alternative therapies is summarized in Table 1. Recently, Costales *et al.*, compared clicked small molecule drugs with oligonucleotides<sup>49</sup>. They showed that morpholino-oligonucleotides had superior specificity *in vivo* when targeting myotonic dystrophy type 2 (DM2) associated gene alterations. Especially, therapeutic poly-oligonucleotides assembled on site had superior activity when compared to small molecule drugs. In addition, conjugation with CPPs was found to dramatically enhance the therapeutic performance of PMOs used to target exon skipping in the mouse mdx model<sup>50</sup>.

Multidrug resistance is an issue that blocks the use of available small molecule drugs<sup>49</sup>. It was shown that using siRNA and ULANAR PS antisense/siRNA makes cancer cells more permeable and reduces resistance. Wu *et al.*, proposed a novel copolymer decorated with folic acid and siRNA for breast cancer treatment<sup>51</sup>. Co-delivery with doxorubicin resulted in suppression of tumor growth while maintaining rather low toxicity on other tissues. In another work was reported that multidrug resistance could be reversed using click polymer/iMDR1-pDNA complex nanoparticles<sup>56</sup>. This approach could become useful in breast cancer and other solid tumor treatments in cases when conventional therapy is not working and to reduce the toxicity.

Macrophages could be targeted by siRNA via click mannosylated polymeric micelles<sup>52</sup>. Being involved in cancer and atherosclerosis pathology, macrophages represent an important therapeutic target. CD206 (mannose receptor) is primarily expressed on macrophages which ensured specific delivery of mannose-decorated siRNA micelles. Up to a 13-fold higher siRNA concentration was found in the macrophages compared to CD206 negative control cells which supports the high specificity of the approach. The authors underline that this approach is general and can be adopted for click functionalization with other target ligands to direct siRNA delivery<sup>52</sup>.



Main competitors to gene therapeutics remain small molecule drugs<sup>53</sup>. Small molecules have the advantage of well controlled chemical composition and low cost. However, many of them suffer from poor water solubility and high toxicity. Additionally, cells often become resistant to small molecule drugs, via mutagenesis<sup>57</sup>. It is worth noting that the therapeutic action of these drugs can be improved by click chemistry as well<sup>53-54</sup>. The drugs can be used in mixed formulations with siRNA,<sup>51</sup> or they can be covalently conjugated to antibodies and nucleic acids including aptamers<sup>55</sup>.

Lastly, the synthesis of biodegradable polymers is an exciting approach that could solve the issue of drug clearance from the blood stream. Zhao *et al.*, prepared disulfide - containing copolymers and showed that they are useful for gene delivery<sup>58</sup>.

## 5. Conclusions

In summary, click chemistry finds a growing amount of applications in the development of gene therapeutics and is now being applied for direct oligonucleotide modification, cargo functionalization or the preparation of nucleotide variants at the nucleoside level. Click chemistry on DNA is relatively well established, whereas RNA modification by click chemistry requires further improvements. The sensitivity of unmodified RNA to chemical reagents and enzymes puts a high demand on the conditions for modifications.

Among prepared molecules, peptide-oligonucleotide conjugates and oligonucleotide nanomaterials show the best therapeutic performance. It is exciting that observations to date suggest gene therapeutics can reverse drug resistance from virus and solid tumors. Delivery and intracellular uptake remain the rate-limiting step, but this issue plagues all therapeutic developments. However, it is convincing from recent developments described in this review that these two issues can be successfully overcome using appropriate design and conjugation strategies.

Compared with small molecule drugs, the high cost of synthetic oligonucleotides and peptides is another obstacle for gene therapy application. Nevertheless, given the rapid development in oligonucleotide and peptide syntheses and the low cost of click chemistry reagents, the overall therapeutic price is bound to fall as the field progresses.

Recent discoveries in RNA biology also provide new targets for clicked therapeutics. Examples are miRNA and lncRNA<sup>59-62</sup>. Following the development of new clickable nucleosides, nucleotides and oligonucleotide modification reagents, targeting regulatory RNAs is an exciting new direction that might bring new advances to the field of synthetic gene therapeutics.

## Acknowledgments

**Funding.** KA, MT, JU and AC acknowledge Villum Foundation (grant no. 13152) for financial support. KVM acknowledges support by NIAID PO1 AI099783-01 and R01 AI111139-01.




## Literature cited

1. Geary RS, Norris D, Yu R, Bennett CF. Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. *Adv Drug Deliv Rev.* 2015; 87:46–51. [PubMed: 25666165]
2. Gooding M, Malhotra M, Evans JC, Darcy R, O'Driscoll CM. Oligonucleotide conjugates - Candidates for gene silencing therapeutics. *Eur J Pharm Biopharm.* 2016; 107:321–40. [PubMed: 27521696]
3. Zagorovsky K, Chou LY, Chan WC. Controlling DNA-nanoparticle serum interactions. *Proc Natl Acad Sci U S A.* 2016; 113(48):13600–13605. [PubMed: 27856755]
4. Lorenzer C, Dirin M, Winkler A-M, Baumann V, Winkler J. Going beyond the liver: Progress and challenges of targeted delivery of siRNA therapeutics. *Journal of Controlled Release.* 2015; 203:1–15. [PubMed: 25660205]
5. Awino JK, Gudipati S, Hartmann AK, Santiana JJ, Cairns-Gibson DF, Gomez N, Rouge JL. Nucleic Acid Nanocapsules for Enzyme-Triggered Drug Release. *Journal of the American Chemical Society.* 2017; 139(18):6278–6281. [PubMed: 28440640]
6. Han J, Wang X, Liu L, Li D, Suyaola S, Wang T, Baigude H. “Click” chemistry mediated construction of cationic curdlan nanocarriers for efficient gene delivery. *Carbohydrate Polymers.* 2017; 163:191–198. [PubMed: 28267496]
7. O'Brien PJ, Elahipanah S, Rogozhnikov D, Yousaf MN. Bio-Orthogonal Mediated Nucleic Acid Transfection of Cells via Cell Surface Engineering. *ACS Central Science.* 2017; 3(5):489–500. [PubMed: 28573212]
8. Che Harun NF, Takemoto H, Nomoto T, Tomoda K, Matsui M, Nishiyama N. Artificial Control of Gene Silencing Activity Based on siRNA Conjugation with Polymeric Molecule Having Coil–Globe Transition Behavior. *Bioconjugate Chemistry.* 2016; 27(9):1961–1964. [PubMed: 27506383]
9. Mongis A, Piller F, Piller V. Coupling of Immunostimulants to Live Cells through Metabolic Glycoconjugate and Bioorthogonal Click Chemistry. *Bioconjugate Chemistry.* 2017; 28(4):1151–1165. [PubMed: 28297599]
10. Warminski M, Kowalska J, Jemielity J. Synthesis of RNA 5'-Azides from 2'-O-Pivaloyloxymethyl-Protected RNAs and Their Reactivity in Azide–Alkyne Cycloaddition Reactions. *Organic Letters.* 2017; 19(13):3624–3627. [PubMed: 28636394]
11. Uchida H, Itaka K, Uchida S, Ishii T, Suma T, Miyata K, Oba M, Nishiyama N, Kataoka K. Synthetic Polyamines to Regulate mRNA Translation through the Preservative Binding of Eukaryotic Initiation Factor 4E to the Cap Structure. *Journal of the American Chemical Society.* 2016; 138(5):1478–1481. [PubMed: 26811205]
12. Nguyen K, Fazio M, Kubota M, Nainar S, Feng C, Li X, Atwood SX, Bredy TW, Spitale RC. Cell-Selective Bioorthogonal Metabolic Labeling of RNA. *Journal of the American Chemical Society.* 2017; 139(6):2148–2151. [PubMed: 28139910]
13. Akbalik G, Langebeck-Jensen K, Tushev G, Sambandan S, Rinne J, Epstein I, Cajigas I, Vlatkovic I, Schuman EM. Visualization of newly synthesized neuronal RNA in vitro and in vivo using click-chemistry. *RNA Biology.* 2017; 14(1):20–28. [PubMed: 27801616]
14. Yoon HI, Yhee JY, Na JH, Lee S, Lee H, Kang S-W, Chang H, Ryu JH, Lee S, Kwon IC, Cho YW, Kim K. Bioorthogonal Copper Free Click Chemistry for Labeling and Tracking of Chondrocytes In Vivo. *Bioconjugate Chemistry.* 2016; 27(4):927–936. [PubMed: 26930274]
15. Lee S, Yoon HI, Na JH, Jeon S, Lim S, Koo H, Han S-S, Kang S-W, Park S-J, Moon S-H, Park JH, Cho YW, Kim B-S, Kim SK, Lee T, Kim D, Lee S, Pomper MG, Kwon IC, Kim K. In vivo stem cell tracking with imageable nanoparticles that bind bioorthogonal chemical receptors on the stem cell surface. *Biomaterials.* 2017; 139:12–29. [PubMed: 28582715]
16. Tyler DS, Vappiani J, Caneque T, Lam EYN, Ward A, Gilan O, Chan Y-C, Hienzsch A, Rutkowska A, Werner T, Wagner AJ, Lugo D, Gregory R, Ramirez Molina C, Garton N, Wellaway CR, Jackson S, MacPherson L, Figueiredo M, Stolzenburg S, Bell CC, House C, Dawson S-J, Hawkins ED, Drewes G, Prinjha RK, Rodriguez R, Grandi P, Dawson MA. Click chemistry enables preclinical evaluation of targeted epigenetic therapies. *Science.* 2017; 356(6345):1397–1401. [PubMed: 28619718]


17. Turner AM, Ackley AM, Matrone MA, Morris KV. Characterization of an HIV-targeted transcriptional gene-silencing RNA in primary cells. *Hum Gene Ther.* 2012; 23(5):473–83. [PubMed: 22122263]
18. Matsui M, Sakurai F, Elbashir S, Foster DJ, Manoharan M, Corey DR. Activation of LDL receptor expression by small RNAs complementary to a noncoding transcript that overlaps the LDLR promoter. *Chem Biol.* 2010; 17(12):1344–55. [PubMed: 21168770]
19. von Maltzahn G, Ren Y, Park JH, Min DH, Kotamraju VR, Jayakumar J, Fogal V, Sailor MJ, Ruoslahti E, Bhatia SN. In vivo tumor cell targeting with "click" nanoparticles. *Bioconjug Chem.* 2008; 19(8):1570–8. [PubMed: 18611045]
20. Lutz JF, Zarafshani Z. Efficient construction of therapeutics, bioconjugates, biomaterials and bioactive surfaces using azide-alkyne "click" chemistry. *Advanced drug delivery reviews.* 2008; 60(9):958–70. [PubMed: 18406491]
21. Wiessler M, Waldeck W, Pipkorn R, Kliem C, Lorenz P, Fleischhacker H, Hafner M, Braun K. Extension of the PNA world by functionalized PNA monomers eligible candidates for inverse Diels Alder Click Chemistry. *International journal of medical sciences.* 2010; 7(4):213–23. [PubMed: 20617125]
22. Pipkorn R, Wiessler M, Waldeck W, Hennrich U, Nokihara K, Beining M, Braun K. Improved synthesis strategy for peptide nucleic acids (PNA) appropriate for cell-specific fluorescence imaging. *International journal of medical sciences.* 2012; 9(1):1–10. [PubMed: 22211082]
23. Wojciechowska M, Ruczynski J, Rekowski P, Alenowicz M, Mucha P, Pieszko M, Miszka A, Dobkowski M, Bluijssen H. Synthesis and hybridization studies of a new CPP-PNA conjugate as a potential therapeutic agent in atherosclerosis treatment. *Protein and peptide letters.* 2014; 21(7): 672–8. [PubMed: 24654853]
24. Narenji H, Gholizadeh P, Aghazadeh M, Rezaee MA, Asgharzadeh M, Kafil HS. Peptide nucleic acids (PNAs): currently potential bactericidal agents. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.* 2017; 93:580–588. [PubMed: 28686972]
25. Taskova M, Mantsiou A, Astakhova K. Synthetic Nucleic Acid Analogues in Gene Therapy: An Update for Peptide-Oligonucleotide Conjugates. *Chembiochem : a European journal of chemical biology.* 2017
26. Kozma E, Demeter O, Kele P. Bio-orthogonal Fluorescent Labelling of Biopolymers through Inverse-Electron-Demand Diels-Alder Reactions. *Chembiochem.* 2017; 18(6):486–501. [PubMed: 28070925]
27. Taskova M, Madsen CS, Jensen KJ, Hansen LH, Vester B, Astakhova K. Antisense Oligonucleotides Internally Labeled with Peptides Show Improved Target Recognition and Stability to Enzymatic Degradation. *Bioconjugate Chemistry.* 2016
28. Maegawa Y, Mochizuki S, Miyamoto N, Sakurai K. Gene silencing using a conjugate comprising Tat peptide and antisense oligonucleotide with phosphorothioate backbones. *Bioorganic & medicinal chemistry letters.* 2016; 26(4):1276–8. [PubMed: 26774656]
29. Raja K, McDonald R, Tuck S, Rodriguez R, Milley B, Traquina P. One-pot synthesis, purification, and formulation of bionanoparticle-CpG oligodeoxynucleotide hepatitis B surface antigen conjugate vaccine via tangential flow filtration. *Bioconjug Chem.* 2007; 18(2):285–8. [PubMed: 17302382]
30. Wang R, He A, Ramu E, Falck JR. Correction: Studies towards asymmetric synthesis of 4(S)-11-dihydroxydocosahexaenoic acid (diHDHA) featuring cross-coupling of chiral stannane under mild conditions. *Organic & biomolecular chemistry.* 2015; 13(7):2196. [PubMed: 25609001]
31. Lou C, Martos-Maldonado MC, Madsen CS, Thomsen RP, Midtgaard SR, Christensen NJ, Kjems J, Thulstrup PW, Wengel J, Jensen KJ. Peptide-oligonucleotide conjugates as nanoscale building blocks for assembly of an artificial three-helix protein mimic. *Nature communications.* 2016; 7:12294.
32. O'Donovan L, Okamoto I, Arzumanov AA, Williams DL, Deuss P, Gait MJ. Parallel synthesis of cell-penetrating peptide conjugates of PMO toward exon skipping enhancement in Duchenne muscular dystrophy. *Nucleic acid therapeutics.* 2015; 25(1):1–10. [PubMed: 25412073]

33. Ghosh PS, Hamilton AD. Supramolecular dendrimers: convenient synthesis by programmed self-assembly and tunable thermoresponsivity. *Chemistry (Weinheim an der Bergstrasse, Germany)*. 2012; 18(8):2361–5.
34. Cavalieri F, Postma A, Lee L, Caruso F. Assembly and functionalization of DNA-polymer microcapsules. *ACS nano*. 2009; 3(1):234–40. [PubMed: 19206271]
35. Alshaer W, Hillaireau H, Vergnaud J, Ismail S, Fattal E. Functionalizing Liposomes with anti-CD44 Aptamer for Selective Targeting of Cancer Cells. *Bioconjug Chem*. 2015; 26(7):1307–13. [PubMed: 25343502]
36. Liu T, Xue W, Ke B, Xie MQ, Ma D. Star-shaped cyclodextrin-poly(l-lysine) derivative co-delivering docetaxel and MMP-9 siRNA plasmid in cancer therapy. *Biomaterials*. 2014; 35(12):3865–72. [PubMed: 24486215]
37. O'Mahony AM, Godinho BM, Ogier J, Devocelle M, Darcy R, Cryan JF, O'Driscoll CM. Click-modified cyclodextrins as nonviral vectors for neuronal siRNA delivery. *ACS chemical neuroscience*. 2012; 3(10):744–52. [PubMed: 23077718]
38. Okholm A, Kjems J, Astakhova K. Fluorescence detection of natural RNA using rationally designed "clickable" oligonucleotide probes. *RSC Advances*. 2014; 4(86):45653–45656.
39. Xiong H, Leonard P, Seela F. Construction and assembly of branched Y-shaped DNA: "click" chemistry performed on dendronized 8-aza-7-deazaguanine oligonucleotides. *Bioconjug Chem*. 2012; 23(4):856–70. [PubMed: 22443223]
40. Kaczmarek JC, Kowalski PS, Anderson DG. Advances in the delivery of RNA therapeutics: from concept to clinical reality. *Genome medicine*. 2017; 9(1):60. [PubMed: 28655327]
41. Huang Y. Preclinical and Clinical Advances of GalNAc-Decorated Nucleic Acid Therapeutics. *Molecular therapy. Nucleic acids*. 2017; 6:116–132. [PubMed: 28325278]
42. Nishina K, Unno T, Uno Y, Kubodera T, Kanouchi T, Mizusawa H, Yokota T. Efficient in vivo delivery of siRNA to the liver by conjugation of alpha-tocopherol. *Molecular therapy : the journal of the American Society of Gene Therapy*. 2008; 16(4):734–40.
43. Jeong JH, Mok H, Oh YK, Park TG. siRNA conjugate delivery systems. *Bioconjug Chem*. 2009; 20(1):5–14. [PubMed: 19053311]
44. Zhang HM, Su Y, Guo S, Yuan J, Lim T, Liu J, Guo P, Yang D. Targeted delivery of anti-coxsackievirus siRNAs using ligand-conjugated packaging RNAs. *Antiviral Res*. 2009; 83(3):307–16. [PubMed: 19616030]
45. Wolfrum C, Shi S, Jayaprakash KN, Jayaraman M, Wang G, Pandey RK, Rajeev KG, Nakayama T, Charrise K, Ndungo EM, Zimmermann T, Koteliensky V, Manoharan M, Stoffel M. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. *Nat Biotechnol*. 2007; 25(10):1149–57. [PubMed: 17873866]
46. AnChiu C, Xian W, Moss CF. Flying in silence: Echolocating bats cease vocalizing to avoid sonar jamming. *Proc. Natl. Acad. Sci. U. S. A.* 2008; 105(35):13116–13121. [PubMed: 18725624]
47. Sugo T, Terada M, Oikawa T, Miyata K, Nishimura S, Kenjo E, Ogasawara-Shimizu M, Makita Y, Imaichi S, Murata S, Otake K, Kikuchi K, Teratani M, Masuda Y, Kamei T, Takagahara S, Ikeda S, Ohtaki T, Matsumoto H. Development of antibody-siRNA conjugate targeted to cardiac and skeletal muscles. *Journal of controlled release : official journal of the Controlled Release Society*. 2016; 237:1–13. [PubMed: 27369865]
48. Dalakas MC. Gene therapy for Duchenne muscular dystrophy: balancing good science, marginal efficacy, high emotions and excessive cost. *Therapeutic advances in neurological disorders*. 2017; 10(8):293–296. [PubMed: 28781610]
49. Costales MG, Rzuczek SG, Disney MD. Comparison of small molecules and oligonucleotides that target a toxic, non-coding RNA. *Bioorganic & medicinal chemistry letters*. 2016; 26(11):2605–9. [PubMed: 27117425]
50. Burki U, Keane J, Blain A, O'Donovan L, Gait MJ, Laval SH, Straub V. Development and Application of an Ultrasensitive Hybridization-Based ELISA Method for the Determination of Peptide-Conjugated Phosphorodiamidate Morpholino Oligonucleotides. *Nucleic acid therapeutics*. 2015; 25(5):275–84. [PubMed: 26176274]


51. Wu Y, Zhang Y, Zhang W, Sun C, Wu J, Tang J. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles. *Colloids and surfaces. B, Biointerfaces*. 2016; 138:60–9. [PubMed: 26655793]
52. Yu SS, Lau CM, Barham WJ, Onishko HM, Nelson CE, Li H, Smith CA, Yull FE, Duvall CL, Giorgio TD. Macrophage-specific RNA interference targeting via "click", mannosylated polymeric micelles. *Molecular pharmaceutics*. 2013; 10(3):975–87. [PubMed: 23331322]
53. Kim BS, Lee K, Jung HJ, Bhattarai D, Kwon HJ. HIF-1 $\alpha$  suppressing small molecule, LW6, inhibits cancer cell growth by binding to calcineurin b homologous protein 1. *Biochemical and biophysical research communications*. 2015; 458(1):14–20. [PubMed: 25603055]
54. Sakashita M, Mochizuki S, Sakurai K. Hepatocyte-targeting gene delivery using a lipoplex composed of galactose-modified aromatic lipid synthesized with click chemistry. *Bioorganic & medicinal chemistry*. 2014; 22(19):5212–9. [PubMed: 25155912]
55. Li X, Fang T, Boons GJ. Preparation of well-defined antibody-drug conjugates through glycan remodeling and strain-promoted azide-alkyne cycloadditions. *Angewandte Chemie (International ed. in English)*. 2014; 53(28):7179–82. [PubMed: 24862406]
56. Gao Y, Chen L, Zhang Z, Chen Y, Li Y. Reversal of multidrug resistance by reduction-sensitive linear cationic click polymer/iMDR1-pDNA complex nanoparticles. *Biomaterials*. 2011; 32(6):1738–47. [PubMed: 21112086]
57. Lambert G, Estevez-Salmeron L, Oh S, Liao D, Emerson BM, Tlsty TD, Austin RH. An analogy between the evolution of drug resistance in bacterial communities and malignant tissues. *Nature reviews. Cancer*. 2011; 11(5):375–82. [PubMed: 21508974]
58. Zhao N, Roesler S, Kissel T. Synthesis of a new potential biodegradable disulfide containing poly(ethylene imine)-poly(ethylene glycol) copolymer cross-linked with click cluster for gene delivery. *International journal of pharmaceutics*. 2011; 411(1–2):197–205. [PubMed: 21439364]
59. Renganathan A, Felley-Bosco E. Long Noncoding RNAs in Cancer and Therapeutic Potential. *Advances in experimental medicine and biology*. 2017; 1008:199–222. [PubMed: 28815541]
60. Saayman SM, Ackley A, Burdach J, Clemson M, Gruenert DC, Tachikawa K, Chivukula P, Weinberg MS, Morris KV. Long Non-coding RNA BGas Regulates the Cystic Fibrosis Transmembrane Conductance Regulator. *Molecular therapy : the journal of the American Society of Gene Therapy*. 2016; 24(8):1351–7. [PubMed: 27434588]
61. Sastre B, Canas JA, Rodrigo-Munoz JM, Del Pozo V. Novel Modulators of Asthma and Allergy: Exosomes and MicroRNAs. *Frontiers in immunology*. 2017; 8:826. [PubMed: 28785260]
62. Kayhanian H, Smyth EC, Braconi C. Emerging molecular targets and therapy for cholangiocarcinoma. *World journal of gastrointestinal oncology*. 2017; 9(7):268–280. [PubMed: 28808500]



**Figure 1.** Main principles of click chemistry (**A**), applications of “clicked” diagnostic tools, therapeutics and nanomaterials (**B**). FG1-2 = functional groups that are specific for bioconjugation and unreactive with other biological groups. L = linker.




**Figure 2.** Chemical structures of PNA (1), morpholino (2); Diels Alder (a)<sup>26</sup>, reverse electron-demand Diels-Alder (b) and SPAAC (c) for oligonucleotide-peptide conjugation.




**Figure 3.** Oligonucleotide nanomaterials as gene therapeutics. Functionalization of DNA-Polymer (A) microcapsules;<sup>34</sup> and (B) Liposomes functionalized with CD44 Aptamer<sup>35</sup>.





**Figure 4.**  
 Specific recognition of *BRAFRNA* by internally clicked peptide-oligonucleotide conjugates (POCs)<sup>27</sup>

**Figure 5.**

Approaches of “clicked” therapeutic RNA. siRNA conjugate with lipophilic molecule on a solid CPG support A);<sup>45</sup> Biotinylated siRNA conjugated with streptavidin activated monoclonal antibody B);<sup>46</sup> Thiol-reactive siRNA conjugated with reduced Fab fragment C)<sup>47</sup>.

**Table 1**

Performance metrics of “clicked” gene therapeutics compared to other methods.

#	Oligonucleotide/ small molecule	Mechanism of action/Target	Modification	Stability in biofluids	Specificity	Uptake efficacy	Ref
1	MO-DM2	Antisense/(CCUG) repeat expansion	morpholino	++	+++	++	49
2	PMO-CPP	antisense	morpholino	nd	nd	+++	50
3	P-gp siRNA	siRNA/reducing Pgp expression in breast cancer	“Clicked” triblock copolymer, natural siRNA	+	++	+++	51
4	CD206-siRNA	siRNA/macrophage targeted delivery	Micelle mannosylation by click	++	+++	+++	52
5	LW6	HIV-1 $\alpha$ suppressing	Click with a fluorophore	nd	nd	+++	53
6	D/Gal	Induced gene expression/cancer cell	Clicked galactose	nd	++	++	54
7	ADC	anti-CD22 antibody with doxorubicin/lymph oma cancer cell	-	++	+++	+++	55

+ Moderate, ++ High, +++ Very high